摘要
2019年12月,全球范围爆发了新型冠状病毒(SARS-CoV-2)引发的传染性肺炎,由于SARS-CoV-2传染性强且无特效抗病毒药物,导致SARS-CoV-2迅速全球性蔓延,国内外专家积极投身于抗SARS-CoV-2的研究工作。我国李兰娟院士在体外实验中发现达芦那韦能显著抑制SARS-CoV-2复制,有望成为抗SARS-CoV-2的有效药。因此本文拟对达芦那韦的药理作用、药动学特点、合理使用与药学监护要点进行总结,并综述达芦那韦治疗新型冠状病毒的研究进展,以期为常态化防控SARS-CoV-2提供参考。
In December 2019,infectious pneumonia caused by a new type of coronavirus(SARS-CoV-2) broke out global.As SARS-CoV-2 is highly infectious and has no specific antiviral drugs, it has led to the rapid global spread of SARS-CoV-2.Experts at home and abroad are actively engaged in the research work of anti-SARS-CoV-2.Chinese academician Lanjuan Li found experiments that darunavir could significantly inhibit the replication of SARS-CoV-2 in vitro, and it was expected to become an effective drug against SARS-CoV-2.Therefore, this article summarizes the pharmacological effects, pharmacokinetic characteristics, rational use and key points of pharmaceutical care of darunavir, and summarizes the research progress of darunavir in the treatment of SARS-CoV-2 for providing normalized prevention and control of SARS-CoV-2 reference.
作者
任相霖
陈璐
边原
舒永全
龙恩武
何林
闫峻峰
童荣生
REN Xianglin;CHEN Lu;BIAN Yuan;SHU Yongquan;LONG Enwu;HE Lin;YAN Junfeng;TONG Rongsheng(Personalized Drug Therapy Key Laboratory of Sichuan Province,Department of Pharmacy,Sichuan Academy of Medical Sciences,Sichuan Provincial People’s Hospital,Affiliation Hospital of University of Electronic Science and Technology of China,Chengdu,Sichuan 610072,China;School of Medicine,University of Electronic Science and Technology of China,Chengdu,Sichuan 610054,China)
出处
《今日药学》
CAS
2021年第5期334-338,共5页
Pharmacy Today
基金
国家临床重点专科建设项目(30305030698)
四川省省级公益性科研院所基本科研业务专项课题(2018YSKY0017)
四川省人民医院院级科研基金临床研究及转化项目(2018LY09)
四川省科技计划项目(2021YJ0189)
四川省人民医院个体化药物治疗省重点实验室开放和自拟课题(2018YB06)。
